RxDoctor Payments DataLook up a doctor →

Glenn Parris, MD

Rheumatology · Lawrenceville, GANPI 1417148834

Payments from drug & device makers

$157,892in general payments, 2019–2025

Across 1,535 payments — averaging $102.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$115K
  • Amgen$13K
  • AbbVie$8K
  • UCB, Inc.$5K
  • Johnson & Johnson$4K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $10K from 37 others

What the payments were for

  • Consulting fees$6,48814%
  • Speaking & faculty fees$6,46014%
  • Grants$2401%
  • Travel & lodging$8632%
  • Food & beverage$30,59568%
  • Education$3761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,892 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,613,323
Medicare patients
451
Services billed
99,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept52$382,965
Humira(Cf) PenAdalimumab44$346,430
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5039$346,027
RinvoqUpadacitinib29$193,885
Xeljanz XrTofacitinib Citrate25$147,471
Cosentyx Sensoready (2 Pens)Secukinumab13$109,504
Cosentyx Sensoready PenSecukinumab14$101,176
Enbrel MiniEtanercept13$97,016
BenlystaBelimumab23$95,969
RemicadeInfliximab11$82,125
OtezlaApremilast16$78,015
Cimzia (2 Pack)Certolizumab Pegol11$65,485
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$64,680
ProliaDenosumab30$52,130
Hydroxychloroquine Sulfate181$10,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$42$346,02739 claims
AbbVieRinvoq$7,669$193,88529 claims
AmgenOtezla, Prolia$13,240$130,14546 claims
GSKBenlysta$1,102$95,96923 claims
Johnson & JohnsonRemicade$4,460$82,12511 claims
UCB, Inc.Cimzia (2 Pack)$4,902$65,48511 claims
Hikma Pharmaceuticals USABuprenorphine$15$2,30311 claims
Scilex Pharmaceuticals Inc.Colchicine$17$72213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →